Nasdaq:US$32.17 (+0.00) | HKEX:HK$50.40 (+0.75) | AIM:£4.71 (+0.02)
News & Presentations
Previous Article   |   Next Article
Presentations, Scientific Publications | 3 Jun 2014

ASCO 2014: First-in-human phase I study of a selective VEGFR/FGFR dual inhibitor sulfatinib with milled formulation in patients with advanced solid tumors